Proactive Investors - Run By Investors For Investors

hVIVO says inoculation warrants further development after showing early promise

National Institutes of Health has released part of the data set from a phase I study
The company is developing a vaccine for mosquito-borne diseases

hVIVO PLC (LON:HVO) said its vaccine for mosquito-borne diseases “warrants further development”.

The company made the assertion following the release of partial data from a phase I trial related to safety and humoral response (which relates to the drug’s potential to induce immunity).

hVIVO builds on position of strength in challenge trials

The update on the hVIVO inoculation was released by the National Institutes of Health (NIH), which shared the new information to American Society of Tropical Medicine and Hygiene's annual conference in New Orleans.

"The presentation of these partial preliminary results by NIH at the conference is encouraging regarding safety and immunogenicity responses,” said chairman Trevor Phillips.

“We look forward to seeing the full data when the NIH completes the sample analyses in due course, at which point, a full assessment of the trial results will be possible".

The remaining primary and secondary results from the phase I study “will be evaluated once the full and final data are available”, said hVIVO.

View full HVO profile View Profile

hVIVO PLC Timeline

Related Articles

blood samples in test tubes
October 25 2018
The NYSE-listed company has designed a routine blood test to screen for colorectal and prostate cancers that reduces the need for more invasive colonoscopies and biopsies
June 04 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use